PIERRE CASSIGNEUL, Chief Executive Officer >>
ANTHONY P. SHUBER, M.S., Chief Technology Officer & Co-Founder >>
ANGELO M. DE MARZO, M.D., Ph.D., Chief Medical Officer >>
MARK GIRARDI, Vice President, Sales and Marketing >>
Chief Executive Officer
Mr. Cassigneul has more than 25 years of senior management experience in the healthcare and medical device industries, both in Europe and the United States. Previously, Pierre was vice chairman of the board and formerly president and chief executive officer of XDx Inc. Under his leadership, XDx received Food and Drug Administration (FDA) clearance for and launched the AlloMap® Gene Expression Test for use in transplant management, representing one of the first U.S. molecular diagnostics company to obtain FDA approval of an in vitro diagnostic multivariate index assay (IVDMIA). He joined XDx from the consulting firm, Stone Bridge Management LLC, where he was an operating partner. Formerly, as the vice president of diabetes management at Becton Dickinson & Co, he oversaw completion of the product, clinical trials and regulatory submissions. Pierre has held top management positions at Bayer in the diabetes self-testing business unit, where he developed and launched a new patient-monitoring system; Ortho Diagnostic Systems (J&J) in the AIDS and hepatitis business unit, where he launched a complete line of blood screening products; and Abbott Laboratories in the diagnostic division, where he launched the first HIV test for screening the European blood supply. He served on the board of The Personalized Medicine Coalition. He holds a management degree from the Ecole Superieure de Commerce de Reims, France.
Chief Technology Officer & Co-Founder
Mr. Shuber leads the company's overall scientific efforts and its applied research team. He has more than two decades of experience in highly successful research, development and commercialization of diagnostics and applied genomics. Most recently, Tony served as Co-Founder, Executive Vice President and Chief Technology Officer for EXACT Sciences, an applied genomics company focused on developing proprietary non-invasive, DNA-based screening tools for the early detection of cancer. At EXACT, Tony spearheaded the development of DNA-based molecular technologies used for commercial cancer screening. Previously, he held key scientific, management roles with Genzyme Genetics / Integrated Genetics, as well as earlier research and management positions. Tony holds more than 30 patents and has authored numerous peer-reviewed papers. He earned his undergraduate and graduate degrees from Marquette University in Milwaukee, Wisconsin.
Chief Medical Officer
Dr. De Marzo leads the company’s overall medical and clinical development efforts. Previously, Angelo was a Professor of Pathology, Oncology and Urology and a member of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, where he still maintains an adjunct faculty position. He received his undergraduate, medical and graduate degrees from the University of Colorado. He completed a residency in anatomic pathology at The Johns Hopkins University School of Medicine in 1997 and since 1998 he has been a practicing boarded urological pathologist, focusing extensively on prostate pathology. His research at Johns Hopkins focused on the molecular mechanisms involved in cancer initiation and progression, as well as, the role of inflammation in prostate cancer. He also performed clinical diagnostic, prognostic and predictive biomarker research in urological cancers. Angelo has published more than 200 articles, has served on a number of NIH grant review panels, is a former member of the Department of Defense Prostate Cancer Research Program (PCRP) Integration Panel, and currently serves on the Editorial Board for the journals The Prostate and Cancer Prevention Research.
Vice President, Sales and Marketing
Mr. Girardi leads the company’s commercial operations. He has more than twenty years of extensive sales and marketing experience in both startup and operating companies in the life science, IVD and medical device industries. Before joining Predictive, Mark served as Senior Director of Marketing at Z-Tech Medical where he was responsible for commercialization of the company’s breast cancer screening devices. Previously, as Director of Marketing Diagnostics at Cytyc Corporation (now Hologic), he managed the teams responsible for launch and commercial development of the Thin Prep Imaging System. Mark also held senior marketing positions at GenzymeGenetics and Milligen/Biosearch, a division of Millipore. He holds a B.S in Chemistry from Merrimack College and a M.S. in Chemistry from the University of New Hampshire.